We read with great interest the article entitled \"HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy\" authored by Mak et al(1). The authors proposed that the reverse transcription efficiency in HBeAg-positive patients was significantly higher than that in HBeAg-negative patients, based on the RNA: DNA ratio in the two groups of patients (0.79 vs. 0.53; p\u003c 0.001). We had found that a higher ratio of serum HBV RNA to HBV DNA was inversely related with reverse transcription efficiency of HBV pgRNA(2), and HBeAg-positive patients had a lower reverse transcription efficiency of HBV pgRNA than HBeAg-negative patients did. We here suggest that the ratio of serum HBV DNA: (HBV DNA + HBV RNA) is more reliable to assess the reverse transcriptional efficiency of pgRNA. The medians of ratio in our cohort were 0.56 (n = 54), 0.56 (n = 23), 0.69 (n = 64) and 0.66 (n = 4), for patients with HBeAg-positive chronic infection, HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection, and HBeAg-negative chronic hepatitis, respectively. Inconsistent with the report by Mak et al., our data showed that the reverse transcriptional efficiency was lower in HBeAg-positive patients than in HBeAg-negative patients (0.56 vs. 0.68; p\u003c 0.001). A schematic diagram for illustrating the efficiencies of covalently closed circular DNA (cccDNA) transcription and reverse transcription of pgRNA are shown in Figure 1.